Phase II Clinical Study of SHR-A1811 in Patients With HER2 Expression / Amplification of Locally Advanced Unresectable or Recurrent Metastatic Biliary Tract Cancer
PHASE2RecruitingINTERVENTIONAL
Enrollment
65
Participants
Timeline
Start Date
June 4, 2024
Primary Completion Date
September 30, 2025
Study Completion Date
September 30, 2025
Conditions
HER2 Expression / Amplification in Patients With Biliary Tract Cancer
Interventions
DRUG
SHR-A1811
SHR-A1811
Trial Locations (1)
200032
RECRUITING
Zhongshan Hospital，Fudan University, Shanghai
All Listed Sponsors
lead
Jiangsu HengRui Medicine Co., Ltd.
INDUSTRY
NCT06413745 - Phase II Clinical Study of SHR-A1811 in Patients With HER2 Expression / Amplification of Locally Advanced Unresectable or Recurrent Metastatic Biliary Tract Cancer | Biotech Hunter | Biotech Hunter